ArticleJPGN reports2025
Efficacy of low FODMAP diet in pediatric patients with disorders of gut-brain interaction.
Article in JPGN reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of low FODMAP diet in pediatric patients with disorders of gut-brain interaction.JPGN reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Disorders of gut-brain interaction (DGBIs), including irritable bowel syndrome (IBS), are common among children. Although a diet that is low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) has been proven to help adults with IBS, there is conflicting evidence of its efficacy in pediatric patients. Methods: This was a retrospective chart review of pediatric patients with DGBIs diagnosed by a pediatric gastroenterologist between December 2018 and April 2022 and referred to a dietician for low FODMAP diet (LFD). The diagnosis was based on Rome IV criteria, and the chart review was based on International Classification of Diseases 10 diagnosis codes for DGBIs. Subjective historical assessment was used to define symptom improvement. The causative FODMAP Monash group(s) were identified during the reintroduction phase based on a symptom diary. Results: A total of 58 patients were initially identified (38 females), 47 of whom completed the LFD and followed up. This included 24 patients with IBS-diarrhea predominant (IBS-D), 10 patients with IBS-mixed type (IBS-M), 6 patients with IBS-constipation predominant (IBS-C), and 7 patients with functional abdominal pain (FAP) or functional dyspepsia (FD). Symptom improvement occurred in 22 (91.6%) of IBS-D, 7 (70%) of IBS-M, 3 (50%) of IBS-C, and 3 (42.8%) of FAP/FD. Fructans, garlic, onions, and lactose were the most common offenders. Conclusion: LFD improves symptoms in most patients with DGBIs, particularly those with IBS-D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.